title: Ex vivo culture of primary human fallopian tube epithelial cells.
abstract: Epithelial ovarian cancer is a leading cause of female cancer mortality in the United States. In contrast to other women-specific cancers, like breast and uterine carcinomas, where death rates have fallen in recent years, ovarian cancer cure rates have remained relatively unchanged over the past two decades (1). This is largely due to the lack of appropriate screening tools for detection of early stage disease where surgery and chemotherapy are most effective (2, 3). As a result, most patients present with advanced stage disease and diffuse abdominal involvement. This is further complicated by the fact that ovarian cancer is a heterogeneous disease with multiple histologic subtypes (4, 5). Serous ovarian carcinoma (SOC) is the most common and aggressive subtype and the form most often associated with mutations in the BRCA genes. Current experimental models in this field involve the use of cancer cell lines and mouse models to better understand the initiating genetic events and pathogenesis of disease (6, 7). Recently, the fallopian tube has emerged as a novel site for the origin of SOC, with the fallopian tube (FT) secretory epithelial cell (FTSEC) as the proposed cell of origin (8, 9). There are currently no cell lines or culture systems available to study the FT epithelium or the FTSEC. Here we describe a novel ex vivo culture system where primary human FT epithelial cells are cultured in a manner that preserves their architecture, polarity, immunophenotype, and response to physiologic and genotoxic stressors. This ex vivo model provides a useful tool for the study of SOC, allowing a better understanding of how tumors can arise from this tissue, and the mechanisms involved in tumor initiation and progression.
authors: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
authors: Susan
authors: S
authors: Fotheringham
authors: Keren
authors: K
authors: Levanon
authors: Ronny
authors: R
authors: Drapkin
references: J Ovarian Res. 2009 Sep 28;2(1):12
references: 19781107
references: J Clin Oncol. 2008 Nov 10;26(32):5284-93
references: 18854563
references: Am J Surg Pathol. 2010 Mar;34(3):433-43
references: 20154587
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: Cell Cycle. 2009 Mar 1;8(5):731-5
references: 19221485
references: Oncology (Williston Park). 2010 Jul;24(8):721-8
references: 20718251
references: Nature. 2003 Mar 20;422(6929):322-6
references: 12646923
references: J Oncol. 2010;2010:932371
references: 19746182
references: J Clin Oncol. 2006 Feb 20;24(6):988-94
references: 16461779
references: J Clin Oncol. 2008 Feb 20;26(6):995-1005
references: 18195328
references: N Engl J Med. 2004 Dec 9;351(24):2519-29
references: 15590954
references: Oncogene. 2010 Feb 25;29(8):1103-13
references: 19935705